Insulin Icodec - the once a week long acting insulin from Novo Nordisk | Diabettech - Diabetes and Technology
Insulin icodec: an insulin analogue suited for once-weekly dosing in type 2 diabetes - Media Centre | EASD
Novo Nordisk's insulin icodec beats other insulin therapies in diabetes study | S&P Global Market Intelligence
Novo Nordisk to file for regulatory approval of once-weekly insulin icodec next year
Novo Nordisk poised to fire on all new GLP1 cylinders following the fourth quarter of 2019, but shares fairly valued - MidgardFinance.com
Novo afslutter sidste af seks succesfulde studier med ugentlig insulin - Dagens Medicin
Novo Nordisk's icodec therapy delivers positive data - PharmaTimes
Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment | NEJM
Prediction: This Could Be This Company's Next Billion-Dollar Product | Nasdaq
Molecular Engineering of Insulin Icodec, the First Acylated Insulin Analog for Once-Weekly Administration in Humans | Journal of Medicinal Chemistry
Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing | BMJ Open Diabetes Research & Care
Novo Nordisk Once-Weekly Insulin Comparable to Daily Injections - Type 2 Nation
Novo Nordisk Touts Another Once-Weekly Insulin Icodec Win In Type 2 Diabetes
The promising future of insulin therapy in diabetes mellitus | American Journal of Physiology-Endocrinology and Metabolism
Novo Nordisk once weekly insulin icodec bests Tresiba in lowering blood sugar (NYSE:NVO) | Seeking Alpha
Insulin icodec: an insulin analogue suited for once-weekly dosing in type 2 diabetes - Media Centre | EASD
Insulin Icodec - the once a week long acting insulin from Novo Nordisk | Diabettech - Diabetes and Technology
